NAD+

NAD+ dosing varies significantly based on administration route and therapeutic goals. For IV infusions, initial doses start at 250mg administered over 2-3 hours to assess tolerance, with gradual escalation to 500-750mg per session. Maintenance protocols typically use 500mg 2-3 times weekly. Higher doses (1000mg+) are reserved for intensive protocols under medical supervision. Subcutaneous injection protocols use 100-200mg daily or every other day. Treatment frequency depends on individual response and goals: acute interventions may use daily dosing for 1-2 weeks, while maintenance protocols use 2-3 sessions weekly. Oral NAD+ precursors (NMN, NR) are often used between IV sessions at doses of 250-500mg daily. Close monitoring of energy levels, sleep quality, and tolerance guides dose optimization.

NAD+ therapy typically follows a 'start low and go slow' approach because everyone responds differently. Most people begin with a smaller dose (250mg) given through an IV over 2-3 hours to see how they react. If that goes well, the dose is gradually increased to 500-750mg per session. Think of it like starting a new exercise program - you don't run a marathon on day one. Most people end up with 2-3 IV sessions per week for optimal benefits. Some people prefer daily smaller injections instead of longer IV sessions. The key is finding your personal sweet spot where you get the energy and cognitive benefits without feeling overstimulated or experiencing side effects. Many people also take oral NAD+ boosters on non-treatment days to maintain steady levels.

IV infusion remains the gold standard for NAD+ delivery, using slow infusion rates (typically 2-4 hours) to minimize side effects and maximize cellular uptake. The solution is prepared fresh and administered through standard IV access, with vital sign monitoring throughout the infusion. Subcutaneous injection offers a more convenient alternative, using small volumes (1-2ml) injected into fatty tissue of the abdomen or thigh. Some clinics offer intramuscular injection for intermediate bioavailability. Push IV (rapid injection) is generally avoided due to high incidence of nausea and flushing. Oral NAD+ has poor bioavailability, so most protocols use precursors like nicotinamide riboside (NR) or nicotinamide mononucleotide (NMN) that convert to NAD+ intracellularly. Combination approaches often use IV sessions 2-3 times weekly with oral precursors on off days.

IV infusion remains the gold standard for NAD+ delivery, using slow infusion rates (typically 2-4 hours) to minimize side effects and maximize cellular uptake. The solution is prepared fresh and administered through standard IV access, with vital sign monitoring throughout the infusion. Subcutaneous injection offers a more convenient alternative, using small volumes (1-2ml) injected into fatty tissue of the abdomen or thigh. Some clinics offer intramuscular injection for intermediate bioavailability. Push IV (rapid injection) is generally avoided due to high incidence of nausea and flushing. Oral NAD+ has poor bioavailability, so most protocols use precursors like nicotinamide riboside (NR) or nicotinamide mononucleotide (NMN) that convert to NAD+ intracellularly. Combination approaches often use IV sessions 2-3 times weekly with oral precursors on off days.

Injection Protocol

• •Subcutaneous injection per protocol
• •Rotate injection sites
• •Consistent daily timing
• •Follow protocol guidelines

Monitoring Schedule

• •Regular progress monitoring
• •Health parameter monitoring
• •Laboratory monitoring
• •Safety monitoring